#Japan #Tokyo #GHIT Fund #NTDs #Malaria

GHIT Fund's Significant Investment in Malaria and NTD Research

The Global Health Innovative Technology (GHIT) Fund has made headlines with its latest decision to invest around JPY 1.37 billion (roughly USD 8.5 million) in groundbreaking research and development (R&D) projects targeting malaria and neglected tropical diseases (NTDs). This substantial funding marks a vital step in the fight against these diseases, which continue to ravage communities worldwide, particularly in resource-constrained areas.

Addressing a Global Health Crisis

Malaria alone poses a formidable challenge, affecting over 280 million individuals globally and claiming approximately 610,000 lives annually. The majority of cases occur in Africa, with children under five representing over 75% of those impacted. Furthermore, the Plasmodium falciparum strain of malaria, known for its high fatality rates, necessitates innovative therapies to combat its continuing threat. The GHIT Fund is responding to this urgent need by channeling approximately JPY 700 million (USD 4.4 million) into the preliminary development of a new antimalarial drug. This initiative is being spearheaded by a collaboration including Medicines for Malaria Venture (MMV), Tanabe Pharma in Japan, and the University of Georgia in the United States.

The developers aim to create a treatment with novel mechanisms that can effectively counteract existing drug resistance. The projected outcomes include provisions for chemoprevention and significant treatment advances for relapsing malaria.

Combatting Neglected Tropical Diseases

In addition to malaria, the GHIT Fund is also focusing on eumycetoma, a severely neglected tropical disease that often results in disability and social stigma among affected populations. The organization is investing approximately JPY 330 million (USD 2 million) into a collaborative study led by Eisai Co., Ltd. and the Drugs for Neglected Diseases initiative (DNDi) to evaluate and potentially register a promising treatment—fosravuconazole—in regions such as Kenya, Senegal, and India.

Eumycetoma currently affects numerous under-resourced rural communities, highlighting the imperative for extensive research and reliable treatment options. The Phase II clinical trials conducted in Sudan provided a favorable profile for this therapy, emphasizing the need for further validation to encourage a global introduction and potential WHO recommendations.

Further Investment in R&D Projects

The GHIT Fund's current portfolio includes three additional notable projects funded at approximately JPY 340 million (USD 2.1 million). These involve:

• - Prolyl tRNA synthetase inhibitors as a novel approach in combating malaria, in collaboration with MMV, GlaxoSmithKline, and the University of Tokyo.
• - A Hit-to-Lead project for antimalarial drug development with MMV and DAIICHI SANKYO COMPANY, LIMITED.
• - Screening projects focused on inhibiting Serine Hydroxymethyltransferase (SHMT), which are led by Eisai and MMV, targeting malaria's mechanisms of action.

These innovative approaches signify a broader commitment to tackling the complex challenges associated with these diseases through diversified strategies in drug development.

GHIT Fund’s Commitment to Global Health

The GHIT Fund, which represents a collaborative effort between the Government of Japan, leading pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP), has invested a total of JPY 43.9 billion (USD 274 million) since its inception in 2013. Currently, the portfolio consists of 42 active projects, encompassing 20 discovery initiatives, 13 preclinical projects, and 9 clinical trials, underscoring the relentless efforts to innovate in medical solutions for some of the world's most pressing health crises.

Moving forward, these research projects not only aim to develop new therapeutics but also emphasize the significance of collaborative partnerships in advancing global health innovation. As new treatments emerge, they have the potential to save countless lives and improve the conditions of health in affected regions, paving the way towards eradicating these daunting diseases.